0000899243-22-031603.txt : 20220920 0000899243-22-031603.hdr.sgml : 20220920 20220920180028 ACCESSION NUMBER: 0000899243-22-031603 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220916 FILED AS OF DATE: 20220920 DATE AS OF CHANGE: 20220920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ahrens Brenton Karl CENTRAL INDEX KEY: 0001322927 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 221254657 MAIL ADDRESS: STREET 1: 2765 SAND HILL ROAD CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-16 0 0001659323 Iterum Therapeutics plc ITRM 0001322927 Ahrens Brenton Karl C/O CANAAN PARTNERS 285 RIVERSIDE AVE., SUITE 250 WESTPORT CT 06880 1 0 0 0 Ordinary Shares 2022-09-16 4 S 0 15000 1.9028 D 22246 I See Footnote Ordinary Shares 2022-09-19 4 S 0 15000 1.7652 D 7246 I See Footnote Ordinary Shares 2022-09-20 4 S 0 7246 1.7817 D 0 I See Footnote Ordinary Shares 410 D The number of Ordinary Shares described herein reflect a 15:1 reverse stock split by the Issuer which became effective August 17, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 - $2.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 - $1.81, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Nancy Levenson, as Attorney-in-Fact for Brenton Karl Ahrens 2022-09-20